This white paper highlights the clinical utility of Samsung S-Fusion™, an advanced image fusion technology that enhances the precision of prostate biopsy procedures. Traditional transrectal ultrasound (TRUS)-guided biopsy, while widely used, often misses clinically significant prostate cancers due to its limited ability to visualize cancerous lesions. To address this limitation, Samsung S-Fusion™ fuses pre-acquired multiparametric MRI (mpMRI) with live TRUS imaging to enable real-time, targeted biopsy of suspicious lesions.
The system, implemented on the Samsung RS85 ultrasound platform, features auto-calibration, 3D modeling, deformation correction, and real-time tracking to enhance procedural accuracy. By overlaying mpMRI-detected lesions onto live ultrasound images, clinicians can confidently navigate to and sample clinically relevant areas, reducing unnecessary tissue sampling and improving diagnostic outcomes.
The paper presents clinical findings showing that MRI/TRUS fusion biopsies—enabled by technologies like S-Fusion™—can detect 30% more high-risk cancers and 17% fewer insignificant cancers compared to traditional systematic 12-core biopsies. S-Fusion™ also offers workflow efficiencies, including automated prostate volume measurement and 3D visualization of biopsy paths.
By integrating imaging modalities and providing advanced navigation support, Samsung S-Fusion™ sets a new standard for prostate biopsy accuracy, enabling more effective diagnosis and patient care in prostate cancer screening and treatment planning.
For more insights on multi-modality fusion imaging, explore the white paper on S-Fusion™ for Liver and Prostate .
